METTL2B

Across TCGA pan-cancer cohorts, METTL2B mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated METTL2B data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher METTL2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated METTL2B expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

UCEC, CCRCC, and GBM are the cancer types where METTL2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.882	0.533	.035	16	view →
CCRCC	DFS	Tertile	All	0.582	0.863	.013	16	view →
GBM	OS	Tertile	All	0.711	0.947	.004	6	view →
PDAC	DFS	Median	II,III,IV	0.283	0.573	.028	6	view →
HNSC	DFS	Median	IV	0.786	0.521	.033	4	view →
LUAD	DFS	Quartile	All	0.968	0.800	.037	4	view →
LSCC	OS	Median	III,IV	0.779	0.917	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

METTL2B–UCEC (DFS)

Open the UCEC breakdown →